Summit Therapeutics may have a geography problem with its lung cancer drug ivonescimab.
In a study update reported Sunday, patients from North America and Europe treated with the drug saw their lung cancer return and progress faster than patients from China — a discordant result that could complicate Summit’s plans to secure approval of ivonescimab in the U.S. and Europe.
The risk of tumor progression fell by 45% for participants from China treated with ivonescimab and chemotherapy compared to chemotherapy and a placebo. For participants from Western countries, however, the risk of tumor progression was reduced by 33% — an outcome that failed to reach statistical significance.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
